ILMN Illumina Inc.
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Company profile
Ticker
ILMN
Exchange
Website
CEO
Francis A. deSouza
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ILLUMINA INC
SEC CIK
Corporate docs
IRS number
330804655
ILMN stock data
()
Calendar
30 Oct 20
27 Nov 20
3 Jan 21
News
Financial summary
| Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Jan 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Illumina earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 18 Nov 20 | Mcginnis Karen K | Common Stock | Sell | Dispose S | Yes | 300 | 218 | 65.4K | 1,538 |
| 17 Nov 20 | Jay T Flatley | Common Stock | Sell | Dispose S | Yes | 298.01 | 1,000 | 298.01K | 196,933 |
| 17 Nov 20 | Jay T Flatley | Common Stock | Sell | Dispose S | Yes | 296.73 | 2,000 | 593.46K | 197,933 |
| 14 Nov 20 | Mcginnis Karen K | Common Stock | Payment of exercise | Dispose F | No | 296.73 | 116 | 34.42K | 1,756 |
| 5 Nov 20 | Charles Dadswell | Common Stock | Payment of exercise | Dispose F | No | 311.72 | 882 | 274.94K | 5,154 |
| 5 Nov 20 | Francis A deSouza | Common Stock | Payment of exercise | Dispose F | No | 311.72 | 4,300 | 1.34M | 61,540 |
Institutional ownership Q3 2020
90.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 863 |
| Opened positions | 94 |
| Closed positions | 102 |
| Increased positions | 356 |
| Reduced positions | 293 |
13F shares |
Current |
|---|---|
| Total value | 631.62B |
| Total shares | 131.7M |
| Total puts | 1.74M |
| Total calls | 1.55M |
| Total put/call ratio | 1.1 |
Largest owners |
Shares | Value |
|---|---|---|
| Baillie Gifford & Co | 17.73M | $5.48B |
| BLK BlackRock | 11.75M | $3.63B |
| Vanguard | 11.48M | $3.55B |
| Edgewood Management | 7.15M | $2.21B |
| STT State Street | 6.11M | $1.89B |
| Loomis Sayles & Co L P | 3.5M | $1.08B |
| BK Bank of New York Mellon | 3.26M | $1.01B |
| Sands Capital Management | 3.08M | $951.67M |
| MS Morgan Stanley | 2.62M | $810.68M |
| Capital World Investors | 2.61M | $807.02M |
Financial report summary
?Competition
Thermo Fisher Scientific • BGI • Cerevel Therapeutics • Roche Holding • Solexa • Luminex • Biocept • Agilent • Third Wave • CareDx
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
accessible, achieve, Achieving, addressable, advisory, agree, approval, attract, Bank, beginning, behavioral, beneficial, bridge, capacity, collar, commitment, compliance, copy, decide, decree, delay, depart, departing, depressing, desire, detection, devoted, difficulty, dispose, Disposed, divest, earlier, efficient, enacted, encounter, enforced, enjoining, entitle, entity, EPS, expertise, facility, Failure, favorable, forma, furnished, FY, Goldman, granted, hiring, HSR, impose, injunction, jeopardize, judgment, law, letter, lieu, listing, loan, local, lose, manner, modification, monthly, motivate, omitted, order, organizational, pendency, permitted, preferred, preliminary, preventing, pro, prohibiting, promulgated, rapidly, rata, relationship, renegotiate, replace, request, restraining, restraint, Rodino, settled, shareholder, stockholder, Subtopic, surviving, talent, temporary, unavailable, unsecured, USA, valuable, vest, waiting, waived, waiver
Removed:
higher, involvement
Financial reports
10-Q
2020 Q3
Quarterly report
30 Oct 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
1 May 20
10-K
2019 FY
Annual report
11 Feb 20
10-Q
2019 Q3
Quarterly report
25 Oct 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
26 Apr 19
10-K
2018 FY
Annual report
12 Feb 19
10-Q
2018 Q3
Quarterly report
23 Oct 18
10-Q
2018 Q2
Quarterly report
31 Jul 18
Current reports
8-K
Other Events
10 Nov 20
8-K
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2020
29 Oct 20
8-K
Entry into a Material Definitive Agreement
21 Sep 20
8-K
Departure of Directors or Certain Officers
21 Aug 20
8-K
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020
6 Aug 20
8-K
Submission of Matters to a Vote of Security Holders
1 Jun 20
8-K
Departure of Directors or Certain Officers
12 May 20
8-K
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
30 Apr 20
8-K
Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020
14 Apr 20
8-K
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
6 Feb 20
Registration and prospectus
S-4
Registration of securities issued in business combination transactions
25 Nov 20
425
Business combination disclosure
10 Nov 20
425
Business combination disclosure
2 Nov 20
425
Business combination disclosure
29 Oct 20
425
Business combination disclosure
25 Sep 20
425
Business combination disclosure
22 Sep 20
425
Business combination disclosure
22 Sep 20
425
Business combination disclosure
22 Sep 20
425
Business combination disclosure
22 Sep 20
425
Business combination disclosure
21 Sep 20
Proxies
DEFA14A
Additional proxy soliciting materials
16 Apr 20
DEF 14A
Definitive proxy
16 Apr 20
DEFA14A
Additional proxy soliciting materials
24 May 19
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
PRE 14A
Preliminary proxy
25 Mar 19
DFAN14A
Additional proxy materials by non-management
5 Nov 18
DFAN14A
Additional proxy materials by non-management
2 Nov 18
DEF 14A
Definitive proxy
6 Apr 18
DEFA14A
Additional proxy soliciting materials
6 Apr 18
Other
SD
Conflict minerals disclosure
21 May 20
SD
Conflict minerals disclosure
14 May 19
SD
Conflict minerals disclosure
30 May 18
CT ORDER
Confidential treatment order
9 Mar 18
SD
Conflict minerals disclosure
5 Jun 17
NO ACT
No action letter
25 Jan 17
SD
Conflict minerals disclosure
25 May 16
NO ACT
No action letter
18 Mar 16
CT ORDER
Confidential treatment order
24 Aug 15
SD
Conflict minerals disclosure
29 May 15
Ownership
4
ILLUMINA / JAY T FLATLEY ownership change
19 Nov 20
4
ILLUMINA / KAREN K MCGINNIS ownership change
19 Nov 20
4
ILLUMINA / KAREN K MCGINNIS ownership change
17 Nov 20
4
ILLUMINA / SAM SAMAD ownership change
9 Nov 20
4
ILLUMINA / Oene Mark Van ownership change
9 Nov 20
4
ILLUMINA / SUSAN H TOUSI ownership change
9 Nov 20
4
ILLUMINA / Mostafa Ronaghi ownership change
9 Nov 20
4
ILLUMINA / ROBERT P RAGUSA ownership change
9 Nov 20
4
ILLUMINA / KAREN K MCGINNIS ownership change
9 Nov 20
4
ILLUMINA / Aimee L Hoyt ownership change
9 Nov 20
Patents
APP
Utility
Methods and Compositions for Whole Genome Amplification and Genotyping
26 Nov 20
This invention provides methods of amplifying genomic DNA to obtain an amplified representative population of genome fragments.
APP
Utility
Flexible Seed Extension for Hash Table Genomic Mapping
26 Nov 20
Methods, systems, and apparatuses, including computer programs for generating and using a hash table configured to improve mapping of reads are disclosed that include obtaining a first seed of K nucleotides from a reference sequence, generating a seed extension tree having a nodes, wherein each node of the nodes corresponds to (i) an extended seed that is an extension of the first seed and has a nucleotide length of K* and (ii) one or more locations, in a seed extension table, that include data describing reference sequence locations that match the extended seed, and for each node: storing interval information at a location of the hash table that corresponds to an index key for the extended seed, wherein the interval information references one or more locations in the seed extension table that include reference sequence locations that match the extended seed associated with the node.
APP
Utility
Sensors Having an Active Surface
26 Nov 20
Disclosed in one example is an apparatus including a substrate, a sensor over the substrate including an active surface and a sensor bond pad, a molding layer over the substrate and covering sides of the sensor, the molding layer having a molding height relative to a top surface of the substrate that is greater than a height of the active surface of the sensor relative to the top surface of the substrate, and a lidding layer over the molding layer and over the active surface.
GRANT
Utility
Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
24 Nov 20
The disclosed embodiments concern methods, apparatus, systems and computer program products for determining sequences of interest using unique molecular index (UMI) sequences that are uniquely associable with individual polynucleotide fragments, including sequences with low allele frequencies and long sequence length.
GRANT
Utility
Methods and systems for generation and error-correction of unique molecular index sets with heterogeneous molecular lengths
24 Nov 20
The disclosed embodiments concern methods, apparatus, systems and computer program products for determining sequences of interest using unique molecular index sequences that are uniquely associable with individual polynucleotide fragments, including sequences with low allele frequencies and long sequence length.